ID   MS-EwS-34
AC   CVCL_A0VR
DR   Wikidata; Q108820991
RX   PubMed=30879952;
CC   Sequence variation: Gene fusion; HGNC; HGNC:3446; ERG + HGNC; HGNC:3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (Direct_author_submission).
CC   Miscellaneous: Gene fusion, site of sampling, sex and age of donor from personal communication of Rossig, Claudia.
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): PubMed=30879952
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,11
ST   D16S539: 12
ST   D3S1358: 15,18
ST   D5S818: 11
ST   D7S820: 10,12
ST   FGA: 19,23
ST   TH01: 6,8
ST   TPOX: 8,10
ST   vWA: 16,18
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   10Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 19-12-24; Version: 6
//
RX   PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014; PMCID=PMC6520468;
RA   Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C.,
RA   Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J.,
RA   Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N.,
RA   Muller I., Walles H., Hartmann W., Rossig C.;
RT   "EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for
RT   targeting with gene-modified T cells.";
RL   Mol. Ther. 27:933-946(2019).
//